Sun Pharma announces approval to mkt Razadyne tm Tablets

20864 Investors following Sun Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sun Pharma announces approval to mkt Razadyne tm Tablets

Sun Pharma announces USFDA tentative approval to market generic Razadyne tm Tablets

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Sun Pharma announces approval to mkt Sinemet CR tablets Buy Sun Pharma; target Rs 1287: Share khan Research Sun Pharma to raise Rs 35bn for generic acquisitions Sun Pharmaceutical: Sales growth 23%, Profit up 29% ALSO READ See latest News about Sun Pharma See previous management interviews See what other Experts & Brokerages are saying about Sun Pharma Sun Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Sun Pharma?

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted tentative approval for the company's Abbreviated New Drug Application (ANDA) for generic Razadyne tm, galantamine tablets.

Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

These generic versions of galantamine are bio-equivalent to Razadyne tm distributed by Ortho-McNeil Neurologics, Inc. The ANDA includes three strengths: tablets containing galantamine hydrobromide equivalent to 4mg, 8 mg and 12 mg base.

These strengths of branded galantamine have annual sales of approximately USD 120 million in the US.

Razadyne tm is a trademark of Johnson & Johnson. 

Sourced from: Sun Pharmaceutical Industries Ltd